CR8722A - Composiciones de metadona para uso topico y metodos para el uso de las mismas - Google Patents

Composiciones de metadona para uso topico y metodos para el uso de las mismas

Info

Publication number
CR8722A
CR8722A CR8722A CR8722A CR8722A CR 8722 A CR8722 A CR 8722A CR 8722 A CR8722 A CR 8722A CR 8722 A CR8722 A CR 8722A CR 8722 A CR8722 A CR 8722A
Authority
CR
Costa Rica
Prior art keywords
compositions
methods
metadona
same
topical
Prior art date
Application number
CR8722A
Other languages
English (en)
Inventor
J Caldwell Larry
S Galer Bradley
Original Assignee
Caldwell Galer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35393974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caldwell Galer Inc filed Critical Caldwell Galer Inc
Publication of CR8722A publication Critical patent/CR8722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen metodos y composiciones para la administracion de metadona a un individuo. Las facetas de la invencion incluyen el empleo de una formulacion de metadona para uso topico, tal como por ejemplo un parche o una formulacion analoga para uso topico. Los metodos y composiciones de la presente invencion pueden ser empleados en una variedad de aplicaciones, tal como por ejemplo en el tratamiento de una variedad de tipos diferentes de dolor.
CR8722A 2004-04-29 2006-11-02 Composiciones de metadona para uso topico y metodos para el uso de las mismas CR8722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56668604P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
CR8722A true CR8722A (es) 2007-05-30

Family

ID=35393974

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8722A CR8722A (es) 2004-04-29 2006-11-02 Composiciones de metadona para uso topico y metodos para el uso de las mismas

Country Status (21)

Country Link
US (1) US20050244486A1 (es)
EP (1) EP1740162A4 (es)
JP (1) JP5250257B2 (es)
KR (1) KR20070007850A (es)
CN (1) CN1976689A (es)
AR (1) AR048878A1 (es)
AU (2) AU2005244214B2 (es)
BR (1) BRPI0510428A (es)
CA (1) CA2563489C (es)
CR (1) CR8722A (es)
EA (1) EA011423B1 (es)
IL (1) IL178661A0 (es)
ME (1) MEP25008A (es)
MX (1) MXPA06012563A (es)
NO (1) NO20065455L (es)
NZ (1) NZ550963A (es)
RS (1) RS20060605A (es)
TW (1) TW200605870A (es)
UA (1) UA88464C2 (es)
WO (1) WO2005110381A1 (es)
ZA (1) ZA200608923B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499067T3 (es) * 2005-10-13 2014-09-26 Nitto Denko Corporation Preparación transdérmica de nicotina y método de producción de la misma
US20080220062A1 (en) * 2006-10-23 2008-09-11 Psivida, Inc. Sustained release of agents for localized pain management
JP5704801B2 (ja) * 2008-08-21 2015-04-22 ニプロパッチ株式会社 粘着性組成物及び経皮吸収型製剤
GB2481619B (en) * 2010-06-30 2012-06-20 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
EP2852571A4 (en) 2012-05-23 2015-11-25 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
WO2022155179A2 (en) * 2021-01-14 2022-07-21 The Trustees Of Indiana University Methods to predict effects of perioperative administration of methadone to optimize pain relief and avoid adverse effects

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
WO1994010987A1 (en) * 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
JP2001517493A (ja) * 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
DE19850517B4 (de) * 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003523405A (ja) * 2000-02-22 2003-08-05 セレジー カナダ インコーポレイテッド 睡眠改善のための方法および組成物
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
ES2286331T3 (es) * 2001-10-22 2007-12-01 3M Innovative Properties Company Envase para parche transdermico/transmucosa.
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment

Also Published As

Publication number Publication date
AU2005244214B2 (en) 2010-02-18
NO20065455L (no) 2007-01-19
BRPI0510428A (pt) 2007-10-30
MXPA06012563A (es) 2007-03-21
EA011423B1 (ru) 2009-02-27
MEP25008A (en) 2010-10-10
AU2010201707A1 (en) 2010-05-20
CA2563489C (en) 2013-06-18
US20050244486A1 (en) 2005-11-03
CN1976689A (zh) 2007-06-06
TW200605870A (en) 2006-02-16
KR20070007850A (ko) 2007-01-16
WO2005110381A1 (en) 2005-11-24
EP1740162A1 (en) 2007-01-10
UA88464C2 (ru) 2009-10-26
IL178661A0 (en) 2007-02-11
JP5250257B2 (ja) 2013-07-31
JP2007538008A (ja) 2007-12-27
CA2563489A1 (en) 2005-11-24
EA200601776A1 (ru) 2007-04-27
NZ550963A (en) 2008-11-28
ZA200608923B (en) 2008-05-28
RS20060605A (sr) 2008-09-29
AU2005244214A1 (en) 2005-11-24
EP1740162A4 (en) 2009-11-18
AR048878A1 (es) 2006-06-07

Similar Documents

Publication Publication Date Title
CR8722A (es) Composiciones de metadona para uso topico y metodos para el uso de las mismas
MX353841B (es) Composiciones antimicrobianas y metodos de uso.
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
GT199900203A (es) Composiciones de celecoxib.
ATE384534T1 (de) Lösung zur nagel-verwendung
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
HN2003000206A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
UY28175A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
AR048963A1 (es) Formulaciones de interferon de hidrogel de poloxamero
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis
AR045872A1 (es) Uso de aminoacidos basicos en formulaciones fungicidas que contienen cobre, composiciones fungicidas y procedimiento para prepararlas
EA200500175A1 (ru) Соль морфин-6-глюкуронида
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
UY31541A1 (es) 1(2)h-tetrazol-5-il-fenil-oxazolidinona s como agentes antibacterianos
UY29133A1 (es) Amidas conteniendo (!!2-tert-butil-1-(tetrahidro-2h-piran-4-ilmetil)-1h-bencimidazol-5-!!) (metil)amino!sulfonilo) como sustituyente. procedimiento de preparacion, composiciones que lo contienen y aplicaciones
AR038666A1 (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y un acido 4-oxobutanoico y uso de la misma para el tratamiento de la diabetes
AR029718A1 (es) Composicion farmaceutica a base de cocaetileno y su utilizacion para el tratamiento de la dependencia de las substancias psicoactivas
UY26840A1 (es) Composición farmacéutica a base de cocaetileno y su utilización para el tratamiento de la dependencia a las sustancias psicoactivas

Legal Events

Date Code Title Description
FC Refusal